Rocket Lab: Hypersonic Tests Drive Growth, But Q2 Margins Face a Squeeze

A successful early-morning launch from Virginia has given Rocket Lab fresh operational momentum, while the broader space sector basks in the glow of SpaceX’s upcoming public listing. But beneath the surface of the “Curveball” mission lies a more complicated picture—one where blistering revenue growth coexists with persistent net losses and a narrowing profit margin.

The suborbital flight, conducted under the HASTE programme using a modified Electron rocket, lifted off from Launch Complex 2 and is designed to test hypersonic technologies for a government client. Terms of the contract remain classified, but the mission underscores a growing revenue stream: hypersonic tests now account for nearly a third of Rocket Lab’s planned launches. That tilt toward defence-related work helped swell the company’s order book to over $2.2 billion, following a first quarter that delivered roughly $200 million in revenue.

Rocket Lab’s operational reliability has become a selling point at a moment when a rival stumbled. Blue Origin suffered a setback in late May when an engine test on its New Glenn rocket failed. The incident has sharpened investor focus on proven flight records, and Rocket Lab’s consistent track record places it in a favourable light as the SpaceX IPO roadshow wraps up on Thursday. Traders have been rotating capital into space equities in anticipation of the listing, and Rocket Lab has been a direct beneficiary.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

Yet the numbers from the first quarter reveal the cost of rapid expansion. Revenue surged 63.5% year on year to $200.3 million, but the gross margin touched 38.2%. For the second quarter, management has guided revenue of $225 million to $240 million with a gross margin not exceeding 35%—a step back from Q1’s level. Below the top line, the company posted a net loss of $45 million, and operating cash outflow reached $50.3 million. To fund that burn, Rocket Lab raised $463.3 million through equity placements, leaving it with $1.2 billion in cash and $177.9 million in short-term securities—a cushion management considers necessary given the capital-intensive nature of the business.

Investors reacted to the launch and the broader sector tailwind by pushing the stock up 5.67% to $111.01, extending the year-to-date gain to 46.09%. Technically, the shares trade comfortably above their 50-day moving average of $99.93, and the relative strength index of 47.9 suggests the stock has cooled from overbought territory. With the next Electron mission not expected until June 2026 at the earliest and more than 70 missions already booked, the pipeline looks solid.

All eyes are now on the year-end debut of the Neutron rocket, a medium-lift vehicle that could cement Rocket Lab’s standing as a serious competitor. But first, the company must deliver on its Q2 promises. When second-quarter results are released, the market will be watching to see whether the topline hits the $225 million-to-$240 million target and whether the margin compression is a temporary blip or a trend. At a market capitalisation of $63.6 billion, the valuation leaves no room for error.